EDWARDS LIFESCIENCES CORP

Markowitz Wayne’s July 30, 2026 sale at Edwards Lifesciences signals short‑term liquidity play amid rising social‑media buzz and high valuation multiples.

Bruls Annette’s modest 109‑share sale at Edwards Lifesciences signals routine liquidity needs, not a warning—insider buying stays strong and the company’s growth outlook remains solid.

Edwards Lifesciences insiders buying RSUs and options signal confidence in its growth, boosting investor confidence in high‑growth heart‑valve tech.

Insider sale of 567 shares by Edwards Lifesciences SVP Andrew M. Dahl – what this signals for investor confidence and future stock performance.

Edwards Lifesciences insider trading: Bobo’s rapid buy‑sell patterns reveal a cautious yet bullish stance—watch for short‑term volatility around earnings and product launches.

CEO Bernard Zovighian’s recent 47,207‑share purchase in Edwards Lifesciences signals modest insider confidence amid a near‑52‑week low, highlighting routine trading and solid fundamentals for long‑term value.

Insider trades show CFO Ullem Scott’s confidence in Edwards Lifesciences—buy‑sell cycle highlights strategic confidence and a strong future outlook.

Edwards Lifesciences insider Bobo Donald E Jr. buys shares at $59.26, reinforcing long‑term confidence amid solid growth and a low 52‑week price, yet still modest dilution for investors.

Edwards Lifesciences insider Lippis Daniel J. buys 12,820 shares in a quiet market, signaling confidence in the TAVR business and recent regulatory win. This move suggests long‑term upside despite short‑term volatility.

CEO Bernard J’s large buy of 25,350 Edwards Lifesciences shares shows bullish insider confidence, potentially boosting the stock past its 52‑week low.